ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,667.56
0.08%
Dow Jones
41,985.35
0.08%
US Dollar vs MXN
20.2392
0.00%
Brent Oil
71.775
0.00%
Bitcoin
84,021.50
-0.03%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Europa
  5. EU

  6. Groupe Bruxelles Lambert SA (GBLB) Cotización

Groupe Bruxelles Lambert SA

Groupe Bruxelles Lambert SA (GBLB)

EU
70.30
0.40
(0.57%)
Cerrado 22 Marzo 10:30AM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
70.30
Postura de Compra
69.40
Postura de Venta
70.50
Volume Operado de la Acción
536,674
69.30 Rango del Día 70.30
62.65 Rango de 52 semanas 72.40
Capitalización de Mercado [m]
10.313B
Precio Anterior
69.90
Precio de Apertura
69.60
Hora
2088
@
70.3
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
112,346
Acciones en circulación
146,700,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
5.98
Beneficio por acción (BPA)
11.75
turnover
6.72B
Beneficio neto
1.72B

Acerca de Groupe Bruxelles Lambert SA

Sector
Investors, Nec
Industria
Investors, Nec
Sitio web
www.gbl.be
Sede
Brussels, Brussels-capital Region, Bel
Fundado
-
Groupe Bruxelles Lambert SA is listed in the Investors sector of the Euronext with ticker GBLB. The last closing price for Groupe Bruxelles Lambert was 69.90 €. Over the last year, Groupe Bruxelles Lambert shares have traded in a share price range of 62.65 € to 72.40 €.

Groupe Bruxelles Lambert currently has 146,700,000 shares in issue. The market capitalisation of Groupe Bruxelles Lambert is 10.25 € billion. Groupe Bruxelles Lambert has a price to earnings ratio (PE ratio) of 5.98.

GBLB Últimas noticias

Más noticias
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
12.33.382352941186870.36711105269.00219743DE
42.63.8404726735667.770.76713062669.07261893DE
125.27.9877112135265.170.764.3511234667.55730522DE
262.053.0036630036668.2570.962.6510669967.18750651DE
520.60.86083213773369.772.462.659940868.07096281DE
156-23.52-25.069281603193.8296.7662.6514178874.64878603DE
2606.189.6381784154764.12105.0562.6515546079.08137755DE

GBLB - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Groupe Bruxelles Lambert?
El precio actual de las acciones de Groupe Bruxelles Lambert es 70.30 €
¿Cuántas acciones de Groupe Bruxelles Lambert están en circulación?
Groupe Bruxelles Lambert tiene 146,700,000 acciones en circulación
¿Cuál es la capitalización de mercado de Groupe Bruxelles Lambert?
La capitalización de mercado de Groupe Bruxelles Lambert es EUR 10.25B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Groupe Bruxelles Lambert?
Groupe Bruxelles Lambert ha negociado en un rango de 62.65 € a 72.40 € durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Groupe Bruxelles Lambert?
El ratio precio/beneficio de Groupe Bruxelles Lambert es 5.98
¿Cuál es el ratio de efectivo a ventas de Groupe Bruxelles Lambert?
El ratio de efectivo a ventas de Groupe Bruxelles Lambert es 1.54
¿Cuál es la moneda de reporte de Groupe Bruxelles Lambert?
Groupe Bruxelles Lambert presenta sus resultados financieros en EUR
¿Cuál es el último ingresos anual de Groupe Bruxelles Lambert?
El último ingresos anual de Groupe Bruxelles Lambert es EUR 6.72B
¿Cuál es el último beneficio anual de Groupe Bruxelles Lambert?
El último beneficio anual de Groupe Bruxelles Lambert es EUR 1.72B
¿Cuál es la dirección registrada de Groupe Bruxelles Lambert?
La dirección registrada de Groupe Bruxelles Lambert es 24, AVENUE MARNIX, BRUSSELS, BRUSSELS-CAPITAL REGION, B-1000
¿Cuál es la dirección del sitio web de Groupe Bruxelles Lambert?
La dirección del sitio web de Groupe Bruxelles Lambert es www.gbl.be
¿En qué sector industrial opera Groupe Bruxelles Lambert?
Groupe Bruxelles Lambert opera en el sector INVESTORS, NEC

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
CLEXCumulex NV
0.88 €
(43.09%)
100
MLOCTOctopus Biosafety
0.134 €
(34.00%)
101
MLWEYWeya
0.019 €
(26.67%)
3.25k
ALEUPEuroplasma
0.0138 €
(24.32%)
97.44M
POXELPoxel
0.22 €
(24.29%)
5.01M
ALKLAKlarsen
0.761 €
(-50.90%)
493.15k
ALCYBCybergun
0.0001 €
(-50.00%)
68.51M
SGDDSSpineguard DS
0.0001 €
(-50.00%)
778.85k
DMSBSDiagnostic Medical Systems
0.005 €
(-50.00%)
3k
HAFDSHaffner Energy DS
0.013 €
(-39.53%)
278.57k
ATOAtos SE
0.004 €
(8.11%)
1.16B
BCPBanco Comercial Portugues SA
0.5448 €
(-0.91%)
152.4M
ALALOAcheterLouerFR
0.0022 €
(4.76%)
99.26M
ALEUPEuroplasma
0.0138 €
(24.32%)
97.44M
ALCYBCybergun
0.0001 €
(-50.00%)
68.51M

Discusión

Ver feed completo
Krungster10 Krungster10 50 segundos hace
Sounds like you have some type of hero complex to think you are out here saving grown folks that are making their own financial decisions. Who are you to tell anyone what not to buy with their own money?
ASII
Truthsocial Truthsocial 53 segundos hace
Exactly absolutely
RDGL
Bigfootbud Bigfootbud 2 minutos hace
Ok, cool! Looks like trumpcancer.com has been registered since 7/25/2005!! Long time!

WHOIS search results
Domain Information
NameTRUMPCANCER.COMRegistry Domain ID189029673_DOMAIN_COM-VRSN
Registered On 2005-07-25 T 23:53:48Z
Expires On 2025-07-25 T 23:53
VRSN
fung_derf fung_derf 3 minutos hace
Keep howling at the moon Fung. Nobody is selling $DBMM.


Or buying it seems.
Therefore, no one need post here and yet here you are!
DBMM
Ayock Ayock 3 minutos hace
Your cult doesn't seem to care...

https://scontent-lax3-1.xx.fbcdn.net/v/t39.30808-6/485739739_1125751009656472_2638257754763246620_n.jpg?_nc_cat=110&ccb=1-7&_nc_sid=833d8c&_nc_ohc=HIFOXUeljRQQ7kNvgGrTA7E&_nc_oc=Adn0mhz5WMG-x509_zDcd6MVHfJ6fcxqBTy9s64GUlNo8agAot8eeruhg_067v4UsOBzoWnSo
Steady_T Steady_T 3 minutos hace
Once approval comes, your threatened lawsuit will be years before it could possibly have results, assuming it is not dismissed early on.

Not something I'm worried about at the present time.
NWBO
Bubae Bubae 4 minutos hace
D your really think anyone is buying that line. You will need to do better to flip your position. $11 a shares. Meanwhile the weekly conversions continue next week with a basis price of $0.0003. You think maybe they should be holding for $11.00. The price of ECVO at $11.00 is a very thinly and very
ASII
ddls ddls 4 minutos hace
Yes, thanks for all the BIEL-bullshit throughout the-years. 🤠

One more week and my March share volume comes out.

I can tell you as of current numbers they're not looking too good.

The pumpaholoic's better come up with something good this week or M
BIEL
WALLnut WALLnut 5 minutos hace
You wouldn’t know “keeping it real” if it smacked you in the face. Your entire argument is built on a deliberate misrepresentation of what makes a medical technology valuable.

Yes, RadioGel’s original patents are old—but you conveniently ignore the fact that Vivos has developed and se
RDGL
vuletini vuletini 7 minutos hace
Fake news
XRPUSD
hotmeat hotmeat 8 minutos hace
Not even close to being the same liar......you've been informed of this FACT repeatedly and yet you continue to maliciously promote this false narrative.

Good thing for us Vivos shareholders no one believes your incessant mindless drivel. lol
RDGL
fung_derf fung_derf 8 minutos hace
Why do Professors teach when they can do instead? Why do you hate educators so?
You talk of kids picking noses and people have no reason for educating.
Why are you so opposed to objectivity and balance on a board?
Did you get picked on a lot in school for being slow?
DBMM
Eagle1 Eagle1 9 minutos hace
Hope Everyone has a great and safe weekend!
GDVM
jondoeuk jondoeuk 12 minutos hace
It is too risky for IPSC, so I will watch from the sidelines. As for FATE, I will wait to see the data (FT819) that should be presented at the EULAR Congress, in June.
IPSC
sortagreen sortagreen 12 minutos hace
These are some rookie numbers here...

Three killed and 15 injured in New Mexico mass shooting
3 hours ago
Kayla Epstein

Three people were killed and 15 others injured in a mass shooting between two rival groups at an unsanctioned car show on Friday in the
Paulie Cashews Paulie Cashews 13 minutos hace
So, what's your problem with the ad? Seems like a good deal - just answer a few questions, and they'll send you a free Gift Card.

I'm sure they'll keep your Social Security number and credit card info safe and secure!

Or, you could pay up and buy an IHUB subscription, a
ksquared ksquared 13 minutos hace
California Dems nervous about Republicans speaking out — and possibly losing control
By Susan Shelley Published March 22, 2025, 11:00 a.m. ET Other Assembly Republicans were removed from their committees after such “offenses” as opposing the bullet train, warning that the state’s mishandl
manibiotech manibiotech 13 minutos hace
Except they don't have data on any of those cancers listed in the table to apply for an approval . Before you point to any early stage or phase 1 trials , I think my statement is clear about the data they can actually use to apply for an approval. 
NWBO
johnydollar johnydollar 14 minutos hace
Can one say it loud, myopic 👀........

😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹
DBMM
fung_derf fung_derf 15 minutos hace
Now, you can't state you're done posting here then start again.
For the record, I have never shorted a stock in my 30 years of investing. Even when I can see it would be the smart thing to do.
I also, don't take positions in penny stocks and shorting one seems silly considering all the
ERHE
SC8 SC8 15 minutos hace
How is Radiogel "groundbreaking" when it was invented over two decades ago, all the original patents have expired and RDGL has at least one competitor we know of that beat them to human trials back in 2022?

Just keeping it real.
RDGL
DTGoody DTGoody 16 minutos hace
AFFU Management if you are reading this message board put out some news and get your stock price back up to a respectable level! I am relativity new here, but you have longs who have toughed out the rough times with your company prior to Covid who deserve a lot better. For their sake do not screw ov
AFFU
WALLnut WALLnut 17 minutos hace
The Future of Cancer Treatment: Why RadioGel® Will Be a Game-Changer After IDE Approval and What’s Next for IsoPet®

RadioGel® is on the verge of redefining cancer treatment, especially for localized tumors that are difficult to remove surgically or treat with traditional radiation the
RDGL

Su Consulta Reciente

EU
GBLB
Groupe Bruxelles Lambert
UNSW
NIIFIETH
NiiFiToken
LBNK
CREUSDT
CarryToken
Delayed Upgrade Clock
ADVFN Logo
México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios